Sanofi India declares INR 117 dividend, announces strong FY24 results

Sanofi India Limited (SANOFI) announced robust financial results for the fourth quarter and year ended December 31, 2024, highlighted by an 8% increase in net sales for Q4. Standalone Profit from Operations for the quarter reached INR 108 crores. Reflecting confidence in its performance, the board recommended a final dividend of ₹117 per equity share, subject to shareholder approval at the upcoming Annual General Meeting. The diabetes portfolio, featuring Toujeo® and the recently launched Soliqua®, showed strong double-digit growth. Partnerships in the Central Nervous System (CNS) and Cardiovascular (CV) categories have been set up foundations for future acceleration and reach. The company also reported a 21% increase in operating profit for Q4 compared to the prior year. Amidst demerger of its consumer healthcare business to Sanofi Consumer Healthcare India Limited (SCHIL).